****Sponsored by Primetime Profiles, LLC
Zacks initiated coverage on Cosmos Health and assigned a $4.50 per share valuation based on a discounted cash flow (DCF) analysis
Zacks projects Cosmos Health revenues to grow from approximately $64.4 million in 2025 to $98.6 million in 2026
Cosmos Health has implemented a digital asset allocation program, including the purchase of Ethereum (ETH)
READ THE INVESTOR PRESENTATION HERE
________________________
Hello Everyone,
We are back with something explosive sitting under .50 with explosive bounce potential.
Pull up COSM right now.
Cosmos is a vertically integrated healthcare group with operations spanning pharmaceuticals, nutraceuticals, pharmaceutical distribution, manufacturing, and an expanding portfolio of technology- and services-oriented assets. Over the past several years, the company has deliberately combined stable, cash-generating businesses in Europe with targeted acquisitions and internal research initiatives aimed at improving revenue quality and unlocking higher-growth opportunities. This strategy has created a diversified platform designed to balance recurring commercial revenues with higher-margin and higher-upside growth drivers.
Just yesterday Zacks Investment Research highlighted Cosmos Health’s diversified revenue base, vertically integrated pharmaceutical and manufacturing operations, technology-enabled initiatives, expansion into the U.S. market, and improving financial performance as key factors supporting its valuation.
Key Highlights from Zacks Small-Cap Research Coverage
Initiation of Coverage with $4.50 Per Share Valuation
Zacks initiated coverage on Cosmos Health and assigned a $4.50 per share valuation based on a discounted cash flow (DCF) analysis, reflecting projected revenue growth, improving gross margins, and a modeled transition toward positive free cash flow over time.
Valuation Methodology
Zacks applied a five-year discounted cash flow framework using a 20% discount rate, reflecting the Company’s small-cap profile and execution risk. The model assumes moderate near-term revenue growth, accelerating in later years, steady improvement in free cash flow margins, and a 2% terminal growth rate.
Strong Revenue Growth Outlook
Zacks projects Cosmos Health revenues to grow from approximately $64.4 million in 2025 to $98.6 million in 2026, with further expansion to over $130 million by 2027, driven by higher-margin pharmaceutical products, branded nutraceuticals, and technology-enabled services.
Vertically Integrated Healthcare Platform
The report highlights Cosmos Health’s vertically integrated operating model, spanning pharmaceutical distribution, GDP-compliant wholesale operations, GMP-certified manufacturing, proprietary nutraceutical brands, telehealth services, and AI-enabled research and development.
U.S. Market Entry
Zacks references Cosmos Health’s expansion into the United States market, highlighted by the acquisition of ZipDoctor, a U.S.-based telehealth subscription platform providing direct-to-consumer access. The report also notes the launch of Sky Premium Life in the U.S. nutraceutical market.
Advancing R&D Pipeline
Zacks references Cosmos Health’s development programs, including CCX0722 for obesity and weight management, as well as additional repurposed compounds targeting multiple sclerosis, allergies, and oncology-related indications, with projects advancing toward clinical and regulatory milestones. These R&D efforts reflect the Company’s focus on identifying and progressing candidates that address large disease markets.
AI-Driven Innovation via Cloudscreen
Zacks identifies the acquisition of Cloudscreen, an AI-enabled drug repurposing and R&D platform, as a key technology supporting Cosmos Health’s research and development activities. The platform uses in silico screening and multimodal biochemical data to identify potential new therapeutic uses for existing compounds, with the goal of shortening development timelines, reducing discovery costs, and supporting potential licensing or development outcomes.
Digital Assets and Blockchain Strategy
The report notes that Cosmos Health has implemented a digital asset allocation program, including the purchase of Ethereum (ETH), supported by a disclosed financing facility of up to $300 million. Zacks also references the Company’s strategic partnership with Prime Ledger LLC to manage digital assets and explore tokenization of intellectual property assets.
Improving Financial Performance and Margin Expansion
Zacks highlights Cosmos Health’s record third quarter of 2025, which included double-digit year-over-year revenue growth, significantly higher gross profit, and improved adjusted EBITDA, reflecting operational execution and a shift toward higher-margin activities.
Greg Siokas, CEO of Cosmos Health, stated: “We are pleased to see Zacks Small-Cap Research initiate coverage of Cosmos Health and recognize the transformation we have been executing across our organization. This coverage underscores the strength of our vertically integrated model, our accelerating revenue growth, and the strategic importance of our investments in AI-driven drug repurposing, proprietary pharmaceutical and nutraceutical brands, and digital health services. As we continue to scale higher-margin products, advance our R&D pipeline, and improve operational efficiency, we believe Cosmos Health is entering an important inflection point with substantial long-term value creation potential for our shareholders.”
At the core of the business, Cosmos owns established pharmaceutical brands such as C-Sept and C-Scrub, alongside nutraceutical brands including Sky Premium Life and Mediterranation. These brands are supported by Cosmofarm, the company’s GDP-compliant distribution and sourcing arm, which services more than a thousand pharmacies and maintains a broad supplier network. The group also operates GMP-certified manufacturing facilities and wholesale operations, enabling tight control across the value chain. This vertically integrated structure provides recurring revenue, operational resilience, and reduced execution risk when launching new consumer healthcare products, while allowing management to pursue multiple, complementary revenue streams through proprietary brands, contract manufacturing, and distribution.
In parallel, Cosmos has expanded its footprint into higher-growth markets and channels. The acquisition of ZipDoctor established a direct-to-consumer telehealth platform in the United States, creating a services-based revenue stream while providing a scalable channel for cross-selling nutraceutical and over-the-counter products. This expansion has been complemented by the launch of Sky Premium Life in the U.S. nutraceutical market, strengthening the company’s presence in one of the world’s largest consumer health markets. Together, these initiatives broaden Cosmos’s commercial reach while deepening engagement with end consumers.
The company has also invested meaningfully in advancing its research and development capabilities. Its development pipeline includes CCX0722 for obesity and weight management, as well as additional repurposed drug candidates targeting multiple sclerosis, allergic conditions, and oncology-related indications. These programs reflect a focused strategy of identifying compounds with established safety profiles and advancing them toward clinical and regulatory milestones in large, underserved disease markets. Supporting this effort is the acquisition of Cloudscreen, an AI-enabled drug repurposing and discovery platform that leverages in silico screening and multimodal biochemical data to accelerate target identification, shorten development timelines, and reduce discovery costs. This technology-driven approach positions Cosmos to pursue higher-margin licensing, partnering, or development outcomes over time.
Recent financial performance underscores the progress of this strategy. The company reported its strongest third quarter on record in 2025, delivering double-digit year-over-year revenue growth alongside meaningful improvements in gross profit and adjusted EBITDA. These results indicate that the ongoing shift toward higher-margin products, services, and technology assets is beginning to be reflected in the financials. Looking ahead, management expects continued revenue expansion over the next several years, driven by growth in branded pharmaceuticals, nutraceuticals, telehealth services, and technology-enabled R&D initiatives.
Finally, Cosmos has demonstrated a willingness to explore innovative capital allocation and infrastructure strategies. The company has implemented a digital asset allocation program that includes the purchase of Ethereum, supported by a disclosed financing facility of up to $300 million. In addition, a strategic partnership with Prime Ledger LLC is intended to support digital asset management and explore the potential tokenization of intellectual property assets. These initiatives highlight management’s broader focus on optionality, innovation, and long-term value creation across both traditional healthcare and emerging digital frameworks.
NEWS
20 hours ago
20 hours ago
Jan 5, 2026
Jan 5, 2026
Cosmos Health Is Building a Platform, and Tariffs Are Accelerating the Strategy
Dec 24, 2025
Cosmos Health is Forcing the Market to Reframe the Conversation
Dec 19, 2025
Dec 3, 2025
Dec 3, 2025
Dec 2, 2025
Dec 2, 2025
Management
SINCERELY,
DISCLAIMER
THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.
OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF SEVEN THOUSAND FIVE HUNDRED USD BY PRIMETIME PROFILES LLC FOR A ONE DAY COSM AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.